Mexidol, 50 mg/ml 5 ml 5 pcs

Mexidol increases the body’s resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication by alcohol and antipsychotic drugs /neuroleptics/).

Mexidol improves cerebral metabolism and blood supply of the brain, improves microcirculation and blood rheology, reduces platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL.

Limits enzymatic toxemia and endogenous intoxication in acute pancreatitis.

Indications

Weakness and fatigue, Dizziness, Concussion and other brain injuries, Heart pain, Attention and memory disorders

• acute cerebral circulation disorders;
• cranial trauma, consequences of craniocerebral injuries;
• dyscirculatory encephalopathy;
• dependent vegetative dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like states;acute myocardial infarction (during the first day) as a part of complex therapy;
• primary open-angle glaucoma of different stages, as a part of complex therapy;
• curing withdrawal syndrome in alcoholism with predominance of neurotic and vegeto-vascular disorders;
• acute intoxication with antipsychotic agents;
• acute purulent inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as a part of the complex therapy.

.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

1 ml ethylmethylhydroxypyridine succinate50 mg

Associates:

Sodium metabisulfite – 1 mg,

water d/i – up to 1 ml.

How to take, the dosage

I/m or intravenously (by jet or drip). When infusion method of administration the drug should be diluted in 0.9% sodium chloride solution.

Inject Mexidol® by jetting slowly over 5 to 7 minutes, by drip at a rate of 40 to 60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In case of acute disturbances of cerebral circulation Mexidol® is used in the first 10-14 days – by IV drops 200-500 mg 2-4 times a day, then by IV drops 200-250 mg 2-3 times a day for 2 weeks.

In case of craniocerebral trauma and craniocerebral injury sequelae Mexidol® is used for 10 to 15 days with 200 to 500 mg by IV drip 2 to 4 times daily.

In patients with dyscirculatory encephalopathy in the decompensation phase Mexidol® should be administered by IV streams or by drop infusion at a dose of 200-500 mg 1 to 2 times daily during 14 days. Then 100 to 250 mg/day in a v/m dose for the next 2 weeks.

For course prophylaxis of discirculatory encephalopathy the drug is administered in a monthly dose of 200-250 mg 2 times a day for 10 to 14 days.

In mild cognitive impairment in elderly patients and in patients with anxiety disorders the drug is used in a daily dosage of 100 to 300 mg/day in a daily dose for 14 to 30 days.

. In acute myocardial infarction within complex therapy Mexidol® is administered intravenously or intramuscularly during 14 days against the background of traditional therapy of myocardial infarction including nitrates, beta-adrenoblockers, angiotensin-converting enzyme inhibitors (ACE), thrombolytics, anticoagulant and antiaggregant agents and symptomatic agents by indications.

In the first 5 days, for maximum effect the drug should be administered intravenously; in the next 9 days Mexidol® can be given intramuscularly.

Intravenous administration of the drug is carried out by drop infusion slowly (in order to avoid side effects) with 0.9% sodium chloride solution or 5% dextrose (glucose) solution in the volume of 100-150 ml during 30-90 minutes. If necessary, slow trickle administration of the drug, lasting at least 5 minutes, is possible.

Injection of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6 – 9 mg/kg of body weight per day; a single dose is 2 – 3 mg/kg of body weight. The maximum daily dose should not exceed 800 mg, a single dose – 250 mg.

In open-angle glaucoma of different stages, Mexidol® is administered intramuscularly in 100 to 300 mg/day, 1 to 3 times daily for 14 days as part of complex therapy.

In patients with alcohol withdrawal syndrome Mexidol® is administered in a dose of 200 – 500 mg intravenously by IV drip or intramuscularly 2 – 3 times daily for 5 – 7 days.

In acute intoxication with antipsychotic agents the drug is administered by IV in a dose of 200 to 500 mg/day for 7 to 14 days.

In acute pyo-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) the drug is prescribed in the first day both in the preoperative and in the postoperative period. Administered doses depend on the form and severity of the disease, process prevalence, variants of the clinical course. Withdrawal of the drug should be carried out gradually only after sustained positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis Mexidol® is prescribed in 200 -500 mg 3 times a day, by infusion (in 0.9% sodium chloride solution) and intravenous drip. Mild degree of severity of necrotic pancreatitis – 100 – 200 mg 3 times a day by IV dropwise (in 0.9% sodium chloride solution) and intravenously. Moderate degree of severity – 200 mg 3 times a day, IV drops (in 0.9% sodium chloride solution). A severe course – in a pulse dosage of 800 mg during the first day, with twice-daily administration; then 200 to 500 mg twice daily with gradual reduction of the daily dose. Extremely severe course – in initial dosage of 800 mg daily until stable relief of pancreatogenic shock; after stabilization of condition – 300 – 500 mg 2 times daily by IV dropwise (in 0.9 % sodium chloride solution) with gradual decrease of daily dose.

Interaction

Mexidol reduces the toxic effects of ethanol.

When used together, Mexidol increases the effect of benzodiazepine derivatives, antidepressants, anxiolytics, anti-Parkinsonian and anticonvulsants.

.

Special Instructions

Mexidol can be combined with all drugs used to treat somatic diseases.

Pediatric use

Mexidol is not prescribed in children due to insufficient study of the drug action.

Impact on driving and operating machinery

When using the drug, caution must be exercised while driving motor vehicle and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

In individual cases, especially in predisposed patients with bronchial asthma with hypersensitivity to sulfites, severe hypersensitivity reactions may develop.

.

Contraindications

• acute renal failure;
• acute hepatic failure.
• high individual sensitivity to the drug

In connection with insufficient studying of the drug action – childhood age, pregnancy, breast-feeding.

.

Side effects

Digestive system: rarely – nausea, dry mouth.

Others: rare – allergic reactions.

.

Overdose

Symptoms: possible development of drowsiness.

.

Similarities

Mexifin, Mexiprim, Neurox, Medomexi, Mexicor, Evrin, MetucinVel, Neuromexol